5 Best Sliver Stocks To Invest In 2015

5 Best Sliver Stocks To Invest In 2015: Zalicus Inc.(ZLCS)

Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of drug candidates focusing on the treatment of pain and inflammation. The company?s clinical and preclinical product candidates for pain and inflammatory diseases include Synavive, a glucocorticoid product candidate, which is in Phase 2b clinical development for the treatment of rheumatoid arthritis; Z160, an N-type calcium channel blocker for chronic pain; Z944, a T-type calcium channel blocker to treat acute or chronic inflammatory pain; and N-type and T-type calcium and sodium channel blockers for the treatment of chronic pain. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and Amgen Inc; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as C ombinatoRx, Incorporated and changed its name to Zalicus Inc. in September 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Bryan Murphy]

  Against my better judgment, I'm going to go ahead and chime in on Zalicus Inc. (NASDAQ:ZLCS) again today. I say it's against my better judgment, because the last two times I opined about the near-term future of ZLCS, I caught some flack (despite the fact that the two takes were diametrical opposites of one another). So, I'm sure some members of at least one of those groups is still lingering out there, ready to pounce when I suggest something that doesn't jive with their views on Zalicus. That's ok though. Opposing viewpoints are how we broaden our horizon.

• [By Bryan Murphy]

  It's fun to be right, especially when it comes to picking stocks. Sometimes though, you can be a little too right, too fast, forcing a change i! n the game plan. Well, the good news/bad news is, I was too right, too fast with Zalicus Inc. (NASDAQ:ZLCS). Back on August 30th I pegged ZLCS as a buy-worthy trade, when it was trading at $0.71. It hit a peak of $0.93. That's a move of 31% in just two trading days. Though the gain has since been whittled down to 'only' 17% thanks to the retreat to the current price of $0.834, shares are still overbought, and I still have to advocate selling your short-term trade on the position.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-sliver-stocks-to-invest-in-2015.html